Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Morton

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Chemico-Biological Interactions|November 18, 2005
The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesteraseMichal Harel, Janice L Hyatt, Boris Brumshtein, et al.
Molecular Cancer Therapeutics|November 18, 2003
Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studiesKyoung Jin P Yoon, Erik J Krull, Christopher L Morton, et al.
Research Square|February 6, 2026
Capturing clinically actionable copy number alterations in Wilms tumor using nanopore sequencingLarissa V Furtado, Carolyn Jablonowski, Pandurang Kolekar, et al.
Investigational New Drugs|March 27, 2007
Evaluation of ABT-751 against childhood cancer models in vivoChristopher L Morton, Edward G Favours, Kimberly S Mercer, et al.
Molecular Therapy. Methods & Clinical Development|April 13, 2016
Distribution of AAV8 particles in cell lysates and culture media changes with time and is dependent on the recombinant vectorBryan A Piras, Jason E Drury, Christopher L Morton, et al.
Pediatric Blood & Cancer|October 28, 2010
Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing programPeter J Houghton, Christopher L Morton, Min Kang, et al.
Pediatric Blood & Cancer|June 2, 2011
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, John M Maris, et al.
Pediatric Blood & Cancer|May 4, 2011
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing programChristopher L Morton, John M Maris, Stephen T Keir, et al.
Molecular Pharmacology|March 18, 2005
The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic actionMichal Harel, Janice L Hyatt, Boris Brumshtein, et al.
Surgery|January 31, 2012
Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibitionWayne S Orr, Jason W Denbo, Karim R Saab, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Chemico-Biological Interactions|November 18, 2005
The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesteraseMichal Harel, Janice L Hyatt, Boris Brumshtein, et al.
Molecular Cancer Therapeutics|November 18, 2003
Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studiesKyoung Jin P Yoon, Erik J Krull, Christopher L Morton, et al.
Research Square|February 6, 2026
Capturing clinically actionable copy number alterations in Wilms tumor using nanopore sequencingLarissa V Furtado, Carolyn Jablonowski, Pandurang Kolekar, et al.
Investigational New Drugs|March 27, 2007
Evaluation of ABT-751 against childhood cancer models in vivoChristopher L Morton, Edward G Favours, Kimberly S Mercer, et al.
Molecular Therapy. Methods & Clinical Development|April 13, 2016
Distribution of AAV8 particles in cell lysates and culture media changes with time and is dependent on the recombinant vectorBryan A Piras, Jason E Drury, Christopher L Morton, et al.
Pediatric Blood & Cancer|October 28, 2010
Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing programPeter J Houghton, Christopher L Morton, Min Kang, et al.
Pediatric Blood & Cancer|June 2, 2011
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, John M Maris, et al.
Pediatric Blood & Cancer|May 4, 2011
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing programChristopher L Morton, John M Maris, Stephen T Keir, et al.
Molecular Pharmacology|March 18, 2005
The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic actionMichal Harel, Janice L Hyatt, Boris Brumshtein, et al.
Surgery|January 31, 2012
Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibitionWayne S Orr, Jason W Denbo, Karim R Saab, et al.
Pageof 10